Table 1.
The Intermediate HCC Patients' Demographic
| Characteristics | Total Patients (%) | |
|---|---|---|
| Training group (N=875) | Validation group (N=41) | |
| Sex | ||
| Male | 795 (90.86%) | 40 (97.56%) |
| Female | 80 (9.14%) | 1 (2.44%) |
| Age (years) | ||
| <55 | 445 (50.86%) | 18 (43.90%) |
| ≥55 | 430 (49.14%) | 23 (56.10%) |
| Treatment | ||
| TACE | 632 (72.23%) | 31 (75.60%) |
| Surgery | 206 (23.54%) | 6 (14.64%) |
| None | 37 (4.23%) | 4 (9.76%) |
| AFP (ng/ml) | ||
| ≤400 | 445 (50.85%) | 26 (63.41%) |
| >400 | 386 (44.11%) | 15 (36.59%) |
| NA | 44 (5.02%) | 0 |
| Hgb (g/L) | ||
| ≥120 | 668 (76.34%) | 30 (73.17%) |
| <120 | 207 (23.66%) | 11 (26.83%) |
| PLT (*10^9/L) | ||
| ≥100 | 651 (74.40%) | 26 (63.41%) |
| <100 | 222 (25.37%) | 15 (36.59%) |
| NA | 2 (0.22%) | 0 |
| WBC (*10^9/L) | ||
| <11 | 723 (84.07%) | 38 (92.68%) |
| ≥11 | 137 (15.93%) | 3 (7.32%) |
| AST (U/L) | ||
| ≥40 | 661 (75.54%) | 25 (60.97%) |
| <40 | 214 (24.46%) | 16 (39.03%) |
| NA | 15 (1.71%) | 0 |
| LDH (U/L) | ||
| <245 | 470 (53.78%) | 29 (70.73%) |
| ≥245 | 404 (46.22%) | 12 (26.27%) |
| NA | 1 (0.11%) | 0 |
| ALB (g/L) | ||
| ≥35 | 652 (74.51%) | 30 (73.17%) |
| <35 | 223 (25.49%) | 11 (26.83%) |
| TBIL (umol/L) | ||
| ≥17.1 | 488 (55.77%) | 19 (46.34%) |
| <17.1 | 387 (44.23%) | 22 (53.66%) |
| CRP (mg/L) | ||
| ≥10 | 501 (58.05%) | NA |
| <10 | 362 (41.95%) | NA |
| PT (s) | ||
| <13 | 630 (73.34%) | 27 (65.85%) |
| ≥13 | 229 (26.66%) | 14 (34.15%) |
| NA | 12(1.37%) | 0 |
| Location of lesions | ||
| Both lobes | 504 (57.60%) | 13 (31.70%) |
| Single lobe | 371 (42.40%) | 28 (68.30%) |
| Diameter of main tumor (mm) | ||
| >50 | 585 (66.86%) | 22 (53.66%) |
| ≤50 | 290 (33.14%) | 19 (46.34%) |
| Number of intrahepatic lesions | ||
| >3 | 523 (59.77%) | 30 (73.17%) |
| ≤3 | 352 (40.23%) | 11 (26.83%) |
| aMAP Score | ||
| ≥56 | 551 (62.97%) | 17 (41.46%) |
| 49.42≤aMAP<56 | 181 (20.69%) | 11 (26.83%) |
| <49.42 | 143 (16.34%) | 13 (31.71%) |